Molomics

Molomics is a artificial intelligence company offering a platform for discovery structurally novel small molecule therapeutics using a combination of artificial intelligence and human collective intelligence that is headquartered in Barcelona, Spain and was founded in 2015 by Jascha Blobel.

The platform uses artificial intelligence to predict which drugs will have the desired effect on disease outcomes. The company's in-house drug discovery program focuses on leveraging their software platform for discovery drugs for treating Parkinson's Disease. Their Parkinson's Disease treatment in development focuses on addressing Levodopa Induced Dyskinesia (LIP) by applying GPCRs (G Protein-Coupled Receptors) in the drug discovery and development process. The Molomics drug discovery platform typically has three phases which include a feasibility study, drug design phase, and a partial preclinical analysis.

According to the company's website they are open to creating partnerships for drug discovery and design with pharmaceutical companies interested in leveraging the Molomics drug discovery software platform.